Papargyriou, A., …, and Reichert, M. (2025). Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Nat Biomed Eng 9, 836-864. doi: 10.1038/s41551-024-01273-9
Cover Story. Branched pancreatic cancer organoids reveal heterogeneity-driven tumour state transitions and treatment response.

Randriamanantsoa, S., …, Reichert, M.*, and Bausch, A. R.* (2022). Spatiotemporal dynamics of self-organized branching in pancreas-derived organoids. Nat Commun 13, 5219. doi: 10.1038/s41467-022-32806-y
Defined biophysical rules of self-organized branching in pancreatic organoids; relevant for state transition modelling. *equally contributing

Peschke, K., …, and Reichert, M. (2022). Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. EMBO Mol Med 14, e14876. doi: 10.15252/emmm.202114876
Functional model systems reveal treatment-triggered vulnerabilities in PDAC, providing rationale for exploiting tumour plasticity for personalized therapy frameworks.

Falcomata, C., …, Reichert, M., …, and Saur, D. (2022). Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodelling the tumour microenvironment. Nat Cancer 3, 318-336. doi: 10.1038/s43018-021-00326-1
Identified multi-kinase inhibitor vulnerability in mesenchymal PDAC subtypes enabling immune checkpoint response. Demonstrates lineage-informed therapeutic approach.

Feldmann, K., …, and Reichert, M. (2021). Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Gastroenterology 160, 346-361 e324. doi: 10.1053/j.gastro.2020.09.010
Prrx1-driven plasticity of cancer-associated fibroblasts shapes aggressive PDAC phenotypes. Conceptual evidence for cell-state–driven plasticity in the tumour microenvironment.

Reichert, M.*, …, and Rustgi, A. K.* (2018). Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Dev Cell 45, 696-711 e698. doi: 10.1016/j.devcel.2018.05.025
Cover Story. Demonstrated p120ctn-dependent state-plasticity as key driver of metastatic organotropism. *Co-senior authors.

Reichert, M., …, and Rustgi, A. K. (2013). The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis. Genes Dev 27, 288-300. doi: 10.1101/gad.204453.112
Cover Story. Identified Prrx1 as master regulator of pancreatic plasticity in development, regeneration and carcinogenesis.

Reichert, M., …, and Rustgi, A. K. (2013). Isolation, culture and genetic manipulation of mouse pancreatic ductal cells. Nat Protoc 8, 1354-1365. doi: 10.1038/nprot.2013.079
Established an organotypic 3D pancreatic ductal culture system enabling disease modelling, and early organoid-analog technology.

Patent No.: EP20206259.2, Analysis of tissue samples using quantitative phase-contrast microscopy (2022) – Development of a novel and patented technology for label-free single-cell phenotyping to quantify real-time tumour heterogeneity with potential of clinical implementation (also see doi: 10.1172/jci.insight.169105).

Patent No.: WO2019073031A1, Combination Treatment of Pancreatic Cancer (2017) – Combined inhibition of PI3K informs p110a and ρ110γ as efficient strategy for pancreatic cancer patients (honoured with the Forcheurs Jean-Marie Lehn Award).